Deep Learning Model Using Transthoracic Echocardiograms Can ID A-Fib
By Elana Gotkine HealthDay Reporter
TUESDAY, May 14, 2024 -- A deep learning model using transthoracic echocardiograms (TTEs) can predict patients with active or occult atrial fibrillation (AF), according to a study published online April 13 in npj Digital Medicine.
Neal Yuan, M.D., from the University of California in San Francisco, and colleagues created a two-stage deep learning algorithm using a video-based convolutional neural network model that distinguished whether TTEs were in sinus rhythm or AF and then predicted which of the TTEs in sinus rhythm occurred in patients who had recently experienced AF. The model was trained on 111,319 TTE videos.
The researchers found that in a held-out test cohort, the model was able to differentiate TTEs in AF from those in sinus rhythm with high accuracy (area under the receiver operating characteristic curve [AUC], 0.96; area under the precision-recall curve [AUPRC], 0.91). The model predicted the presence of concurrent paroxysmal AF among TTEs in sinus rhythm (AUC, 0.74; AUPRC, 0.19). In an external cohort of 10,203 TTEs, model discrimination remained similar (AUC, 0.69; AUPRC, 0.34). Performance was similar among patients who were women, were older than 65 years, or had a CHA2DS2VASc score ≥2. Model performance was better than use of clinical risk factors, TTE measurements, left atrial size, or CHA2DS2VASc (AUCs, 0.64, 0.64, 0.63, and 0.61, respectively). Performance was better for an ensemble model in a cohort subset combining the TTE model with an electrocardiogram (ECG) deep learning model than the ECG model alone (AUC, 0.81 versus 0.79).
"Deep learning by TTE may offer additional opportunities to guide patient screening for occult atrial fibrillation by identifying patients who may benefit from more intensive monitoring," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.